ACR Practice Parameter for the Performance of Gallium-68 DOTATATE PET/CT for Neuroendocrine Tumors

    loading  Checking for direct PDF access through Ovid

Abstract

Radiopharmaceuticals targeting cell surface expression of somatostatin receptors (SSTRs) are particularly useful in the evaluation of neuroendocrine tumors. Gallium-68 DOTA-Tyr3-octreotatate (68Ga-DOTATATE) primarily binds to SSTR type 2 receptors. 68Ga DOTATATE PET/CT is proven to have high impact on the management of neuroendocrine patients compared to traditional anatomical imaging as well as provides additional information over that of conventional nuclear medicine studies (indium-III DTPA-octreotide). It can result in change in management of approximately 75% of patients with neuroendocrine tumors. 68Ga DOTATATE and 18F FDG PET/CT imaging are complementary, with the degree of uptake varying depending on the degree of differentiation of the tumor. Well-differentiated tumors maintain their SSTRs and are positive on 68Ga DOTATATE PET/CT scan, while dedifferentiated tumors are less likely to demonstrate uptake of 68Ga DOTATATE but will demonstrate uptake with 18F FDG PET/CT. In addition, 68Ga DOTATATE PET/CT identifies patients with SSTR expression in their tumors, who have progressed on somatostatin analog therapy, for treatment with 177Lu DOTATATE.

Related Topics

    loading  Loading Related Articles